Better results were obtained in combination regimens with the CCR2 inhibitor PF-04136309 and FOLFIRINOX chemotherapy (leucovorin, fluorouracil, irinotecan, oxaliplatin) in advanced pancreatic cancer, where reduced numbers of both circulating and intratumoral CCR2+ monocytes were measured. This evidence concerns the gene CCR2 and familial pancreatic carcinoma.